Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.
Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...
Gross profit for 2024 dropped to $0.5 million ... previously expensed to research and development expenses prior to FDA approval of the 365-day product. Fourth quarter 2024 selling, general ...
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results ...
Financial income, net for the fourth quarter of 2024 was $252,000, a decrease of $216,000 or 46.1% compared to $468,000 for the fourth quarter of 2023. This decrease was primarily due to less interest ...
The gross margin improved significantly from 25% in the fourth quarter of 2023 to 37% in the fourth quarter of 2024. This expansion in profitability helped ImmuCell swing to a net income of $ ...